Japanese Society for Cell & Gene Therapy
June 13, 2020 - June 15, 2020
A study looking at 10,500 health records of advanced non-small cell lung cancer (aNSCLC) patients from ASCO’s CancerLinQ database found that the use of expanded clinical trial inclusion criteria, as proposed by ASCO and Friends of Cancer Research in 2017, would nearly double the percentage of patients eligible to enroll in clinical trials – from 52.3% to 98.5%. The expanded clinical trial eligibility criteria would allow aNSCLC patients with brain metastases, previous or concurrent cancers, and limited kidney function to enroll in clinical trials.
Considering the recent rapid pandemic state of COVID-19 all over the world and the its potential impact on health of our attendees, speakers, faculty, exhibitors and staff, the president and Boards of Directors (BOD) of the society have just made the difficult decision to cancel the JSGCT2020 in Fukuoka, July 13-15.
During the 25-year history of the society, this is the first time to cancel the JSGCT Annual Meeting.